Physician profile
Julia Accetta
NPI 1811457575
$4,698.26
in general payments reported to CMS, 2019-2025
27 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $195 · 2022: $594 · 2023: $614 · 2024: $1,924 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,710 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,710.38 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $809.55 | 2021-2025 | Siliq, Cabtreo, Arazlo |
| Abbvie INC. | $554.31 | 2022-2025 | |
| Ucb, INC. | $509.15 | 2022-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $483.22 | 2024-2025 | Tremfya |
| Genzyme Corporation | $399.50 | 2022-2025 | |
| Pfizer INC. | $321.91 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $300.97 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $221.96 | 2024 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $149.29 | 2023 | |
| Amgen INC. | $139.33 | 2022-2025 | Otezla, Otezla |
| Incyte Corporation | $120.68 | 2022-2024 | Opzelura |
| Dermavant Sciences, INC. | $76.87 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $68.02 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.54 | 2024-2025 | Spevigo |
| Krystal Biotech INC | $63.97 | 2024 | Vyjuvek |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $62.03 | 2024-2025 | Acthar |
| Janssen Scientific Affairs, LLC | $56.84 | 2025 | Tremfya |
| Helsinn Therapeutics (U.S.), INC. | $56.52 | 2022-2024 | Valchlor |
| Regeneron Pharmaceuticals, INC. | $52.94 | 2024 | Dupixent |
| Organon LLC | $30.40 | 2025 | Vtama |
| Blueprint Medicines Corporation | $28.46 | 2025 | Ayvakit |
| Mimedx Group, INC. | $25.12 | 2024 | |
| Genentech USA, INC. | $24.83 | 2022 | |
| Lilly USA, LLC | $21.72 | 2025 | Ebglyss |
| Kyowa Kirin, INC. | $20.89 | 2024 | Poteligeo |
| Botanix Sb INC | $18.75 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $13.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Accetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.